Tag
US FDA
4 articles
Natco Pharma Receives 7 US FDA Observations at Hyderabad Facility
Natco Pharma discloses US FDA inspection conclusion at its Kothur formulations plant with 7 procedural observations.
The inspection occurred from November 12-20, 2026, at the company's Hyderabad-based
Natco Pharma Receives 7 US FDA Observations at Hyderabad Plant
Natco Pharma received seven procedural observations from US FDA after inspection of its Kothur formulation plant from November 12-20, 2026.
The company expressed confidence in addressing all observati
Aurobindo Pharma Subsidiary US FDA Inspection Closed VAI
Aurobindo Pharma discloses US FDA inspection closure for its subsidiary Apitoria Pharma's API facility.
The Unit-VI facility received a Voluntary Action Indicated (VAI) classification after August 202
Natco Pharma Receives US FDA EIR for Vizag Plant
Natco Pharma received Establishment Inspection Report from US FDA for its Visakhapatnam Finished Dosage Formulations plant.
The FDA inspection conducted in August 2026 resulted in 4 observations on Fo